Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727929 | 1.00 | MAPT (0.56) | MAPTKDM4EHPGDALDH1A1THRB | |
| SCHEMBL7041828 | 0.83 | IMPDH2 (0.56) | MAPTKDM4EHPGDALDH1A1THRB | |
| Hydrochloric Acid SCHEMBL9445578 | 0.82 | IMPDH2 (0.54) | MAPTKDM4EHPGDALDH1A1THRB | |
| SCHEMBL28208179 | 0.80 | KEAP1 (0.44) | MAPTCYP2A6KEAP1PARP1IMPDH2 | |
| SCHEMBL6304703 | 0.80 | CYP2A6 (0.44) | MAPTCYP2A6KEAP1PARP1IMPDH2 | |
| SCHEMBL16688229 | 0.78 | KDM4E (0.57) | MAPTKDM4EHPGDALDH1A1THRB | |
| SCHEMBL13174592 | 0.78 | ALDH1A1 (0.56) | MAPTKDM4EHPGDALDH1A1THRB | |
| SCHEMBL30547023 | 0.78 | ALDH1A1 (0.56) | MAPTKDM4EHPGDALDH1A1THRB | |
| SCHEMBL3116596 | 0.77 | HSD17B10 (0.53) | MAPTKDM4EALDH1A1CYP2A6KEAP1 | |
| SCHEMBL29683700 | 0.77 | PARP1 (0.61) | MAPTKDM4EALDH1A1AHRCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486892-B2 | Polishing composition | FUJIMI INCORPORATED (JP) | 2016-11-08 | — | — | US | claimed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | claimed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | claimed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | claimed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1819341-A2 | IL-12 MODULATORY COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | claimed |
| JP-2007510745-A | — | — | 2007-04-26 | — | — | JP | claimed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | claimed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | claimed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-4013404-A | Method of dyeing hair with indolines, indoles and indazoles | AMERICAN CYANAMID COMPANY (US) | 1977-03-22 | — | — | US | claimed |
| US-20250189895-A1 | METHOD OF MANUFACTURING PLATED ARTICLE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-06-12 | — | — | US | disclosed |
| US-11992914-B2 | Polishing composition, polishing method, and method for producing substrate | FUJIMI INCORPORATED (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-0405425-A2 | Heteroarylamino- and heteroaryloxypyridinamines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4013404-A | Method of dyeing hair with indolines, indoles and indazoles | AMERICAN CYANAMID COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250770-A1 | Fused heterocyclic compounds | IL2, IL4, IL15 | MAPT 1771/4885KDM4E 3523/4885HPGD 197/4885 |
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | MAPT 3259/4885KDM4E 3666/4885HPGD 146/4885 |
| US-20090253694-A1 | Fused hetrocyclic compounds | IL2, IL15, IL4 | MAPT 2861/4885KDM4E 3697/4885HPGD 154/4885 |
| US-20060122156-A1 | Heteroaryl compounds | IL2, CCL11, IL4 | MAPT 2813/4885KDM4E 4005/4885HPGD 231/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | MAPT 3259/4885KDM4E 3666/4885HPGD 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.